Hyb & Seq chemistry is designed to provide unprecedented simplicity of workflow and is compatible with a wide variety of clinical samples such as FFPE, fresh frozen tissue, blood and fine needle aspirates, across a wide variety of applications including RNA and DNA sequencing with both short and long read capabilities. Hyb & Seq chemistry offers the potential for the simplest sequencing workflow, which
"NanoString's Hyb & Seq chemistry has the potential to accelerate the adoption of Next-Generation Sequencing in clinical applications by vastly simplifying the workflow and minimizing the hands-on-time, personnel training, and infrastructure required to set-up and maintain a state-of-the-art NGS laboratory,"
The company will also be presenting the following posters at the ASHG Annual Meeting.
Program Number: 2876/T
Profiling of Cancer Driver Mutations: Detection of Single Nucleotide Variants (SNV) and Small Indels from Small Amounts of FFPE Sample on the nCounter® Analysis System
Program Number: 2895/F
Title: Multiplex Detection of Lung Cancer Driver Mutations: Simultaneous Assay of Single Nucleotide Variants (SNV) and Fusion Transcripts From Small Amounts of FFPE Samples on the nCounter® Analysis System
Program Number: 2894/T
For more information, please visit www.nanostring.com.
Forward-Looking Statements -
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the eventual commercialization of the Hyb & Seq chemistry, the potential of Hyb & Seq chemistry to accelerate the adoption of Next Generation Sequencing for clinical applications and the anticipated benefits and attributes of Hyb & Seq chemistry. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: risks associated with keeping pace with rapidly changing technology and customer requirements; risks regarding the company's ability to successfully develop and commercialize new products; risks that new market opportunities may not develop as quickly as expected; risks associated with competition in marketing and selling products; risks of increased regulatory requirements; as well as the other risks set forth in the company's filings with the
Doug FarrellVice President, Investor Relations and Corporate Communications DFarrell@NanoString.com
News Provided by Acquire Media